TY - JOUR T1 - STAKEHOLDER ENGAGEMENT IN A COMPARATIVE EFFECTIVENESS/IMPLEMENTATION STUDY TO PREVENT CA-MRSA INFECTION RECURRENCE: CA-MRSA Project (CAMP2) JF - medRxiv DO - 10.1101/2020.07.15.20147496 SP - 2020.07.15.20147496 AU - Brianna D’Orazio AU - Jessica Ramachandran AU - Chamanara Khalida AU - Johana Gonzalez AU - Rhonda G. Kost AU - Kimberly S. Vasquez AU - Teresa H. Evering AU - Getaw Worku Hassen AU - Regina Hammock AU - Rosalee Nguyen AU - Ronette Davis AU - Keenan Millan AU - Claude Parola AU - Barry S. Coller AU - Jonathan N. Tobin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/23/2020.07.15.20147496.abstract N2 - Background Methicillin-Resistant (MRSA) or Methicillin-Sensitive (MSSA) Staphylococcus aureus skin and soft tissue infections (SSTIs) pose serious clinical and public health challenges. Few protocols exist for outpatient education, decolonization and decontamination.Objectives This trial implemented infection prevention protocols in homes via Community Health Workers/promotoras.Methods We engaged clinicians, patients, clinical and laboratory researchers, New-York-based Federally Qualified Health Centers and community hospital Emergency Departments. The Clinician and Patient Stakeholder Advisory Committee (CPSAC) convened in-person and remotely for shared decision-making and trial oversight.Results The trial consented 186 and randomized 119 participants with SSTIs with MRSA (n=59) or MSSA (n=59), completed home visits, obtained surveillance cultures from index patients and household members and sampled household environmental surfaces at baseline and three months.Lessons Learned The retention of the CPSAC during the trial demonstrated high levels of engagement.Conclusions CPSAC was highly effective throughout design and execution by troubleshooting recruitment and home visit challenges.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02566928Funding StatementFunding: PCORI #CER-1402-10800 The statements presented in this article are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRBs of Clinical Directors Network and The Rockefeller UniversityAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing is available for this trial. Contact JNTobin@CDNetwork.org for further details of the types of data that will be available, the available related documents, time frames, and criteria for data sharing. ER -